A cancer syndrome or family cancer syndrome is a genetic disorder in which inherited genetic mutations in one or more genes predispose the affected individuals to the development of cancers and may also cause the early onset of these cancers. Cancer syndromes often show not only a high lifetime risk of developing cancer, but also the development of multiple independent primary tumors. Many of these syndromes are caused by mutations in tumor suppressor genes, genes that are involved in protecting the cell from turning cancerous. Other genes that may be affected are DNA repair genes, oncogenes and genes involved in the production of blood vessels (angiogenesis). Common examples of inherited cancer syndromes are hereditary breast-ovarian cancer syndrome and hereditary non-polyposis colon cancer (Lynch syndrome).
- 1 Background
- 2 Genetics
- 3 Some examples
- 3.1 Fanconi anemia
- 3.2 Familial adenomatous polyposis
- 3.3 Hereditary breast and ovarian cancer
- 3.4 Hereditary non-polyposis colon cancer
- 3.5 Hereditary paraganglioma-pheochromocytoma syndrome
- 3.6 Li-Fraumeni syndrome
- 3.7 MUTYH-associated polyposis
- 3.8 Nevoid basal cell carcinoma syndrome
- 3.9 Von Hippel–Lindau disease
- 3.10 Xeroderma pigmentosum
- 4 References
Hereditary cancer syndromes underlie 5 to 10% of all cancers. Scientific understanding of cancer susceptibility syndromes is actively expanding: additional syndromes are being found, the underlying biology is becoming clearer, and commercialization of diagnostic genetics methodology is improving clinical access. Given the prevalence of breast and colon cancer, the most widely recognized syndromes include hereditary breast-ovarian cancer syndrome (HBOC) and hereditary non-polyposis colon cancer (HNPCC, Lynch syndrome).
Some rare cancers are strongly associated with hereditary cancer predisposition syndromes. Genetic testing should be considered with adrenocortical carcinoma; carcinoid tumors; diffuse gastric cancer; fallopian tube/primary peritoneal cancer; leiomyosarcoma; medullary thyroid cancer; paraganglioma/pheochromocytoma; renal cell carcinoma of chromophobe, hybrid oncocytic, or oncocytoma histology; sebaceous carcinoma; and sex cord tumors with annular tubules.
Two copies of every gene are present in all cells of the body and each one is called an allele. Most cancer syndromes are transmitted in a mendelian autosomal dominant manner. In these cases, only one faulty allele has to be present for an individual to have a predisposition to cancer. Individuals with one normal allele and one faulty allele are known as heterozygous. A heterozygous individual and a person with two normal alleles (homozygous) will have a 50% chance of producing an affected child. The mutation in the inherited gene is known as a germline mutation and a further mutation in the normal allele results in the development of cancer. This is known as Knudson's two hit hypothesis, where the first hit of the gene is the inherited mutation and the second hit occurs later in life. As only one allele needs to be mutated (as compared to both in so called "sporadic cancers"), the individual has a higher chance of developing the cancer than the general population.
Less often, syndromes may be transmitted as an autosomal recessive trait. Both alleles of a gene must be mutated in autosomal recessive disorders for an individual to have a predisposition to cancer. A person with two recessive alleles is known as homozygous recessive . Both parents must have at least one faulty allele in order for a child to be homozygous recessive. If both parents have one mutant allele and one normal allele (heterozygous) then they have a 25% chance of producing a homozygous recessive child (has predisposition), 50% chance of producing a heterozygous child (carrier of the faulty gene) and 25% chance of produced a child with two normal alleles.
Examples of autosomal dominant cancer syndromes are autoimmune lymphoproliferative syndrome (Canale-Smith syndrome), Beckwith–Wiedemann syndrome (although 85% of cases are sporadic), Birt–Hogg–Dubé syndrome, Carney syndrome, familial chordoma, Cowden syndrome, dysplastic nevus syndrome with familial melanoma, familial adenomatous polyposis, hereditary breast-ovarian cancer syndrome, hereditary diffuse gastric cancer (HDGC), hereditary non-polyposis colon cancer (Lynch syndrome), Howel–Evans syndrome of eosophageal cancer with tylosis, juvenile polyposis syndrome, Li-Fraumeni syndrome, multiple endocrine neoplasia type 1/2, multiple osteochondromatosis, neurofibromatosis type 1/2, nevoid basal cell carcinoma syndrome (Gorlin syndrome), Peutz-Jeghers syndrome, familial prostate cancer, hereditary leiomyomatosis renal cell cancer (LRCC), hereditary papillary renal cell cancer (HPRCC), hereditary paraganglioma-pheochromocytoma syndrome, retinoblastoma, tuberous sclerosis, von Hippel-Lindau disease and Wilm's tumor.
Examples of autosomal recessive cancer syndromes are ataxia telangiectasia, Bloom syndrome, Fanconi anemia, MUTYH-associated polyposis, Rothmund-Thomson syndrome, Werner's syndrome and Xeroderma pigmentosum.
Although cancer syndromes exhibit an increased risk of cancer, the risk varies. For some of these diseases, cancer is not their primary feature. The discussion here focuses on their association with an increased risk of cancer. This list is far from exhaustive.
Fanconi anemia (FA) is a disorder with a wide clinical spectrum, including: early onset and increased risk of cancer; bone marrow failure; and congenital abnormalities. The most prominent manifestations of this disorder are those related to hematopoeisis (production of blood by the bone marrow); these include aplastic anemia, myelodysplastic syndrome and acute myeloid leukemia. Hepatic tumors and squamous cell carcinomas of the esophagus, oropharynx and uvula are solid tumors commonly linked to FA. Congenital abnormalities include: skeletal anomalies (especially those affecting the hands), cafe au lait spots and hypopigmentation. To date, the genes known to cause FA are: FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM, FANCN, FANCO, FANCP and BRCA2 (previously known as FANCD1). Inheritance of this syndrome is primarily autosomal recessive, but FANCB can be inherited from the maternal or paternal x-chromosome (x-linked recessive inheritance). The FA pathway is involved in DNA repair when the two strands of DNA are incorrectly joined together (interstrand crosslinks). Many pathways are coordinated by the FA pathway for this including nucleotide excision repair, translesion synthesis and homologous recombination.
Familial adenomatous polyposis
Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome that greatly increases the risk of colorectal cancer. Around 1 in 8000 people will have this disease and it has approximately 100% penetrance. An individual with this disease will have hundreds to thousands of benign adenomas throughout their colon, which will in most cases progress to cancer. Other tumors increased in frequency include; osteomas, adrenal adenomas and carcinomas, thyroid tumors and desmoid tumors. The cause of this disorder is a mutated APC gene, which is involved in β-catenin regulation. Faulty APC causes β-catenin to accumulate in cells and activate transcription factors involved in cell proliferation, migration, differentiation and apoptosis (programmed cell death).
Hereditary breast and ovarian cancer
Hereditary breast-ovarian cancer syndrome (HBOC) is an autosomal dominant genetic disorder caused by genetic mutations of the BRCA1 and BRCA2 genes. In women this disorder primarily increases the risk of breast and ovarian cancer, but also increases the risk of fallopian tube carcinoma and papillary serous carcinoma of the peritoneum. In men the risk of prostate cancer is increased. Other cancers that are inconsistently linked to this syndrome are pancreatic cancer, male breast cancer, colorectal cancer and cancers of the uterus and cervix. Genetic mutations account for approximately 7% and 14% of breast and ovarian cancer, respectively, and BRCA1 and BRCA2 account for 80% of these cases. BRCA1 and BRCA2 are both tumor suppressor genes implicated in maintaining and repairing DNA. Mutations in these genes allow further damage to DNA, which can lead to cancer.
Hereditary non-polyposis colon cancer
Hereditary non-polyposis colon cancer (HNPCC), also known as Lynch syndrome, is an autosomal dominant cancer syndrome that increases the risk of colorectal cancer. It is caused by genetic mutations in DNA mismatch repair (MMR) genes, notably MLH1, MSH2, MSH6 and PMS2. In addition to colorectal cancer many other cancers are increased in frequency. These include; endometrial cancer, stomach cancer, ovarian cancer, cancers of the small bowel and pancreatic cancer. HNPCC is also associated with an early onset of colorectal cancer. MMR genes are involved in repairing DNA when the bases on each strand of DNA do not match. Defective MMR genes allow continuous insertion and deletion mutations in regions of DNA known as microsatellites. These short repetitive sequences of DNA become unstable, leading to a state of microsatellite instability (MSI). Mutated microsatellites are often found in genes involved in tumor initiation and progression, and MSI can enhance the survival of cells, leading to cancer.
Hereditary paraganglioma-pheochromocytoma syndrome
PGL-1 is associated with SDHD mutation, and most PGL-1 individuals with paraganglioma have affected fathers rather than affected mothers. PGL1 and PGL2 are autosomal dominant with imprinting. PGL-4 is associated with SDHB mutation, and is associated with a higher risk of pheochromocytoma, as well as renal cell cancer and non-medullary thyroid cancer.
Li-Fraumeni syndrome is an autosomal dominant syndrome primarily caused by mutations in the TP53 gene, which greatly increases the risk of many cancers and is also highly associated with early onset of these cancers. Cancers linked to this disorder include; soft tissue sarcomas (often found in childhood), osteosarcoma, breast cancer, brain cancer, leukaemia and adrenocortical carcinoma. Individuals with Li-Fraumeni syndrome often have multiple independent primary cancers. The reason for the large clinical spectrum of this disorder may be due to other gene mutations that modify the disease. The protein produced by the TP53 gene, p53, is involved in cell cycle arrest, DNA repair and apoptosis. Defective p53 may not be able to properly perform these processes, which may be the reason for tumor formation. Because only 60-80% of individuals with the disorder have detectable mutations in TP53, other mutations in the p53 pathway may be involved in Li-Fraumeni syndrome.
MUTYH-associated polyposis shares most of its clinical features with FAP; the difference is that it's an autosomal recessive disorder caused by mutations in the MUTYH DNA repair gene. Tumors with increased risk in this disorder are colorectal cancer, gastric adenomas and duodenal adenomas.
Nevoid basal cell carcinoma syndrome
Nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, is an autosomal dominant cancer syndrome in which the risk of basal cell carcinoma is very high. The disease is characterized by basal cell nevi, jaw keratocysts and skeletal abnormalities. Estimates of NBCCS prevalence varies, but is approximately 1 in 60000. The presence of basal cell carcinoma is much higher in white than black individuals; 80% and 38%, respectively. Odontogenic keratocysts are found in approximately 75% of individuals with the disease and often occur early in life. The most common skeletal abnormalities occur in the head and face, but other areas are often affected such as the rib cage. The causative genetic mutation of this disease occurs in the PTCH gene, and the product of PTCH is a tumor suppressor involved in cell signaling. Although the exact role of this protein in NBCCS is not known, it is involved in the hedgehog signaling pathway, known to control cell growth and development.
Von Hippel–Lindau disease
Von Hippel–Lindau (VHL) disease is a rare, autosomal dominant genetic condition that predisposes individuals to benign and malignant tumors. The most common tumors in VHL are central nervous system and retinal hemangioblastomas, clear cell renal carcinomas, pheochromocytomas, pancreatic neuroendocrine tumours, pancreatic cysts, endolymphatic sac tumors and epididymal papillary cystadenomas. VHL results from a mutation in the von Hippel–Lindau tumor suppressor gene on chromosome 3p25.3.
Xeroderma pigmentosum (XP) is an autosomal recessive disorder characterized by sensitivity to ultra-violet (UV) light, massively increased risk of sunburn and increased risk of skin cancers. The risk of skin cancer is more than 10000 times that of normal individuals and includes many types of skin cancer, including melanoma and non-melanoma skin cancers. Also, sun exposed areas of the tongue, lips and eyes have an increased risk of becoming cancerous. XP may be associated with other internal cancers and benign tumors. In addition to cancer, some genetic mutations that cause XP are associated with neurodegeneration. XP may be caused by genetic mutations in 8 genes, which produce the following enzymes: XPA, XPB, XPC, XPD, XPE, XPF, XPG and Pol η. XPA-XPF are nucleotide excision repair enzymes that repair UV light-damaged DNA and faulty proteins will allow the buildup of mutations caused by UV light. Pol η is a polymerase, which is an enzyme involved in DNA replication. There are many polymerases, but pol η is the enzyme that replicates UV light-damaged DNA. Mutations in this gene will produce a faulty pol η enzyme that cannot replicate DNA with UV light damage. Individuals with mutations of this gene have a subset of XP; XP-variant disease.
- Simone Fulda; Heike Allgayer; Helga Rehder (2009). Hereditary Tumors: From Genes to Clinical Consequences. Weinheim: Wiley-VCH. ISBN 3-527-32028-8.
- Hodgson S (January 2008). "Mechanisms of inherited cancer susceptibility". J Zhejiang Univ Sci B 9 (1): 1–4. PMC 2170461. PMID 18196605. doi:10.1631/jzus.B073001.
- Clark AS, Domchek SM (April 2011). "Clinical management of hereditary breast cancer syndromes". J Mammary Gland Biol Neoplasia 16 (1): 17–25. PMID 21360002. doi:10.1007/s10911-011-9200-x.
- Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (July 2009). "Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications". Clin. Genet. 76 (1): 1–18. PMC 2846640. PMID 19659756. doi:10.1111/j.1399-0004.2009.01230.x.
- Banks KC, Moline JJ, Marvin ML, Newlin AC, Vogel KJ. 10 rare tumors that warrant a genetics referral. Fam Cancer. 2013 Mar;12(1):1-18. doi: 10.1007/s10689-012-9584-9. PMID 23377869
- Anderson, Cindy Lou; Carie A Braun (2007). Pathophysiology: functional alterations in human health. Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN 0-7817-6250-2.
- Lindor NM, Greene MH (July 1998). "The concise handbook of family cancer syndromes. Mayo Familial Cancer Program". J. Natl. Cancer Inst. 90 (14): 1039–71. PMID 9672254. doi:10.1093/jnci/90.14.1039.
- Moldovan GL, D'Andrea AD (2009). "How the fanconi anemia pathway guards the genome". Annu. Rev. Genet. 43: 223–49. PMC 2830711. PMID 19686080. doi:10.1146/annurev-genet-102108-134222.
- Tischkowitz MD, Hodgson SV (January 2003). "Fanconi anaemia". Journal of Medical Genetics 40 (1): 1–10. PMC 1735271. PMID 12525534. doi:10.1136/jmg.40.1.1.
- Kee Y, D'Andrea AD (November 2012). "Molecular pathogenesis and clinical management of Fanconi anemia". J. Clin. Invest. 122 (11): 3799–806. PMC 3484428. PMID 23114602. doi:10.1172/JCI58321.
- Kottemann MC, Smogorzewska A (January 2013). "Fanconi anaemia and the repair of Watson and Crick DNA crosslinks". Nature 493 (7432): 356–63. PMID 23325218. doi:10.1038/nature11863.
- Su X, Huang J (September 2011). "The Fanconi anemia pathway and DNA interstrand cross-link repair". Protein Cell 2 (9): 704–11. PMID 21948210. doi:10.1007/s13238-011-1098-y.
- Half E, Bercovich D, Rozen P (2009). "Familial adenomatous polyposis". Orphanet J Rare Dis 4: 22. PMC 2772987. PMID 19822006. doi:10.1186/1750-1172-4-22.
- Galiatsatos P, Foulkes WD (February 2006). "Familial adenomatous polyposis". Am. J. Gastroenterol. 101 (2): 385–98. PMID 16454848. doi:10.1111/j.1572-0241.2006.00375.x.
- Macrae F, du Sart D, Nasioulas S (2009). "Familial adenomatous polyposis". Best Pract Res Clin Gastroenterol 23 (2): 197–207. PMID 19414146. doi:10.1016/j.bpg.2009.02.010.
- Petrucelli N, Daly MB, Feldman GL (May 2010). "Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2". Genet. Med. 12 (5): 245–59. PMID 20216074. doi:10.1097/GIM.0b013e3181d38f2f.
- Smith EC (2012). "An overview of hereditary breast and ovarian cancer syndrome". J Midwifery Womens Health 57 (6): 577–84. PMID 23050669. doi:10.1111/j.1542-2011.2012.00199.x.
- Drescher KM, Sharma P, Lynch HT (2010). "Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients". Clin. Dev. Immunol. 2010: 170432. PMC 2901607. PMID 20631828. doi:10.1155/2010/170432.
- Kunkel TA, Erie DA (2005). "DNA mismatch repair". Annu. Rev. Biochem. 74: 681–710. PMID 15952900. doi:10.1146/annurev.biochem.74.082803.133243.
- Kastrinos F, Syngal S (2011). "Inherited colorectal cancer syndromes". Cancer J 17 (6): 405–15. PMC 3240819. PMID 22157284. doi:10.1097/PPO.0b013e318237e408.
- Neumann HP, Pawlu C, Peczkowska M et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292(8):943. PMID 15328326
- Malkin D (April 2011). "Li-fraumeni syndrome". Genes Cancer 2 (4): 475–84. PMC 3135649. PMID 21779515. doi:10.1177/1947601911413466.
- Bakry, D (2013). P53 in the Clinic: TP53 Germline Mutations: Genetics of Li–Fraumeni Syndrome. New York: Springer. pp. 167–188. ISBN 978-1-4614-3676-8.
- Birch JM (July 1994). "Familial cancer syndromes and clusters". Br. Med. Bull. 50 (3): 624–39. PMID 7987644.
- Quesnel S, Malkin D (August 1997). "Genetic predisposition to cancer and familial cancer syndromes". Pediatr. Clin. North Am. 44 (4): 791–808. PMID 9286285. doi:10.1016/s0031-3955(05)70530-7.
- Sampson JR, Jones N (2009). "MUTYH-associated polyposis". Best Pract Res Clin Gastroenterol 23 (2): 209–18. PMID 19414147. doi:10.1016/j.bpg.2009.03.006.
- Manfredi M, Vescovi P, Bonanini M, Porter S (March 2004). "Nevoid basal cell carcinoma syndrome: a review of the literature". Int J Oral Maxillofac Surg 33 (2): 117–24. PMID 15050066. doi:10.1054/ijom.2003.0435.
- Lo Muzio L (2008). "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)". Orphanet J Rare Dis 3: 32. PMC 2607262. PMID 19032739. doi:10.1186/1750-1172-3-32.
- Richard, S; Gardie, B; Couvé, S; Gad, S (May 30, 2012). "Von Hippel-Lindau: How a rare disease illuminates cancer biology". Seminars in cancer biology 23 (1): 26–37. PMID 22659535. doi:10.1016/j.semcancer.2012.05.005.
- Henry, Todd; Campell, James; Hawley, Arthur (1969). Todd-Sanford clinical diagnosis by laboratory methods, edited by Israel Davidsohn [and] John Bernard Henry. (14th ed.). Philadelphia: Saunders. p. 555. ISBN 0-7216-2921-0.
- Wong WT; n E; Agró Coleman HR et al. (February 2007). "Genotype–phenotype correlation in von Hippel–Lindau disease with retinal angiomatosis". Archives of ophthalmology 125 (2): 239–45. PMC 3019103. PMID 17296901. doi:10.1001/archopht.125.2.239. Retrieved 2008-10-22.
- Lehmann AR, McGibbon D, Stefanini M (2011). "Xeroderma pigmentosum". Orphanet J Rare Dis 6: 70. PMC 3221642. PMID 22044607. doi:10.1186/1750-1172-6-70.
- Niedernhofer LJ, Bohr VA, Sander M, Kraemer KH (2011). "Xeroderma pigmentosum and other diseases of human premature aging and DNA repair: molecules to patients". Mech. Ageing Dev. 132 (6-7): 340–7. PMC 3474983. PMID 21708183. doi:10.1016/j.mad.2011.06.004.